“Expanding Use of Biologics for Personalized Treatment of Eosinophilic-Driven Diseases”
- One prominent trend in the evolution of the global mepolizumab market is the expanding use of biologics for personalized treatment of eosinophilic-driven diseases
- This shift reflects a growing preference for targeted therapies that offer improved efficacy and safety profiles compared to conventional treatments, especially in managing severe asthma and rare eosinophilic disorders
- For instance, mepolizumab’s ability to selectively inhibit interleukin-5 (IL-5) has led to its adoption in treating conditions such as hypereosinophilic syndrome (HES) and EGPA, with ongoing clinical trials exploring its utility in other IL-5–mediated conditions
- This targeted treatment approach is transforming the management of eosinophilic diseases, enabling more personalized care, reducing corticosteroid dependence, and fueling global demand for monoclonal antibody therapies such as mepolizumab
